Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 01 04:00PM ET
1.23
Dollar change
+0.04
Percentage change
3.36
%
IndexRUT P/E- EPS (ttm)-0.90 Insider Own3.41% Shs Outstand191.38M Perf Week-6.82%
Market Cap234.03M Forward P/E- EPS next Y-0.67 Insider Trans-2.01% Shs Float177.81M Perf Month-5.38%
Income-177.08M PEG- EPS next Q-0.20 Inst Own71.60% Short Float3.40% Perf Quarter5.13%
Sales93.16M P/S2.51 EPS this Y44.90% Inst Trans14.08% Short Ratio5.70 Perf Half Y-21.66%
Book/sh0.43 P/B2.84 EPS next Y16.59% ROA-42.28% Short Interest6.04M Perf Year153.61%
Cash/sh1.43 P/C0.86 EPS next 5Y-7.30% ROE-128.02% 52W Range0.41 - 1.93 Perf YTD117.70%
Dividend Est.- P/FCF- EPS past 5Y- ROI-63.71% 52W High-36.20% Beta0.58
Dividend TTM- Quick Ratio4.90 Sales past 5Y-20.42% Gross Margin59.22% 52W Low198.11% ATR (14)0.08
Dividend Ex-Date- Current Ratio5.15 EPS Y/Y TTM44.63% Oper. Margin-145.03% RSI (14)43.49 Volatility6.30% 6.25%
Employees137 Debt/Eq2.76 Sales Y/Y TTM6.17% Profit Margin-190.09% Recom2.71 Target Price3.58
Option/ShortYes / Yes LT Debt/Eq2.49 EPS Q/Q7.01% Payout- Rel Volume0.79 Prev Close1.19
Sales Surprise12.90% EPS Surprise-35.14% Sales Q/Q14.59% EarningsAug 08 AMC Avg Volume1.06M Price1.23
SMA20-7.48% SMA50-4.09% SMA2003.51% Trades Volume842,090 Change3.36%
Date Action Analyst Rating Change Price Target Change
TodayInitiated Piper Sandler Overweight $7
Sep-30-24Resumed BTIG Research Buy $4
Jun-28-24Initiated Rodman & Renshaw Buy $2
Nov-20-23Resumed JP Morgan Underweight
Nov-09-23Upgrade TD Cowen Market Perform → Outperform
May-10-23Upgrade Jefferies Underperform → Hold $1.50 → $1
Feb-24-23Downgrade Jefferies Hold → Underperform $3.20 → $1.50
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Apr-18-22Downgrade Goldman Neutral → Sell $3
Today 08:30AM
Oct-31-24 06:00PM
Oct-29-24 09:00AM
Oct-17-24 12:07PM
Sep-25-24 03:30AM
09:00AM Loading…
Sep-03-24 09:00AM
Aug-13-24 12:00PM
Aug-09-24 10:58AM
Aug-08-24 05:55PM
04:49PM
04:15PM
Aug-01-24 06:00PM
Jun-12-24 09:30AM
May-30-24 06:00PM
May-10-24 04:41PM
03:14PM Loading…
03:14PM
11:33AM
10:35AM
May-09-24 05:39PM
04:15PM
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:13AM
09:00AM
07:19AM
Mar-04-24 05:30PM
04:51PM Loading…
04:51PM
04:42PM
04:15PM
08:30AM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-14-23 07:54AM
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
04:23PM
04:15PM
11:08AM
Aug-07-23 10:23AM
06:30AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
11:31AM
May-10-23 11:28AM
09:16AM
May-09-23 06:45PM
05:41PM
04:15PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
07:29AM
Feb-23-23 06:20PM
05:24PM
04:30PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zalevsky JonathanChief R&D OfficerAug 19 '24Sale1.286,8668,788250,804Aug 20 09:15 PM
Wilson Mark AndrewChief Legal OfficerAug 19 '24Sale1.285,6517,233225,263Aug 20 09:15 PM
ROBIN HOWARD WPresident & CEOAug 19 '24Sale1.2814,88119,048848,358Aug 20 09:14 PM
Wilson Mark AndrewOfficerAug 19 '24Proposed Sale1.285,6517,211Aug 19 04:13 PM
ROBIN HOWARD WOfficerAug 19 '24Proposed Sale1.2814,88118,990Aug 19 04:03 PM
Zalevsky JonathanOfficerAug 19 '24Proposed Sale1.286,8668,762Aug 19 03:45 PM
CHESS ROBERTDirectorJun 14 '24Sale1.2019,50023,400255,273Jun 14 06:02 PM
ROBIN HOWARD WPresident & CEOMay 17 '24Sale1.7516,65029,138863,239May 20 09:14 PM
Zalevsky JonathanChief R&D OfficerMay 17 '24Sale1.757,35512,871257,670May 20 09:13 PM
Wilson Mark AndrewChief Legal OfficerMay 17 '24Sale1.756,26010,955230,414May 20 09:12 PM
Deep Track Capital, LP10% OwnerMay 10 '24Sale1.7856,00099,63018,344,000May 13 04:36 PM
Zalevsky JonathanChief R&D OfficerFeb 20 '24Sale0.689,0146,130265,025Feb 22 08:19 PM
Wilson Mark AndrewChief Legal OfficerFeb 20 '24Sale0.687,6065,172236,674Feb 22 08:17 PM
ROBIN HOWARD WPresident & CEOFeb 20 '24Sale0.6820,03313,622879,889Feb 22 08:16 PM
Zalevsky JonathanChief R&D OfficerNov 17 '23Sale0.499,6464,727274,039Nov 20 09:02 PM
Wilson Mark AndrewChief Legal OfficerNov 17 '23Sale0.497,1793,518243,780Nov 20 09:00 PM
ROBIN HOWARD WPresident & CEONov 17 '23Sale0.4919,8779,740899,922Nov 20 08:58 PM